Augmentation of Hypoxic Pulmonary Vasoconstriction in the Isolated Perfused Rat Lung by In Vitro Antagonists of Endothelium-dependent Relaxation

Valentina L. Brashers, Michael J. Peach, and C. Edward Rose, Jr.
Departments of Internal Medicine and Pharmacology, University of Virginia School of Medicine, Charlottesville, Virginia 22908

Abstract

The role of the endothelium in hypoxic constriction of the intact pulmonary vascular bed has not been clearly elucidated. To test for a possible role for endothelium-derived relaxing factor(s) (EDRF) in the hypoxic pressor response, isolated, whole blood-perfused rat lungs from male Sprague-Dawley rats treated with meclofenamate were prepared. Three protocols were performed, including: (a) normal saline (control); (b) the putative EDRF inhibitors, eicosatetrayenoic acid (ETYA, 1 × 10⁻⁴ M) or nordihydroguaiaretic acid (NDGA, 1 × 10⁻⁴ M) versus vehicle DMSO; and (c) the putative EDRF inhibitor hydroquinone (HQ, 1 × 10⁻⁴ M) versus vehicle ethyl alcohol (ETOH). The pulmonary pressor response to angiotensin II (Ang II, 0.25 μg) injections alternated with 6-min periods of hypoxic ventilation (3% O₂, 5% CO₂) was measured before and after the administration of saline, inhibitors, or vehicles. The administration of the EDRF inhibitors ETYA, NDGA, and HQ resulted in a marked attenuation of the hypoxic pressor response that was not seen in the controls (P < 0.05). In separate experiments, lungs precontracted with norepinephrine (1 × 10⁻⁶ M) were pretreated with edrophonium (1 × 10⁻⁴ M) and then observed for endothelium-dependent vasodilator responses to acetylcholine at increasing doses (1 × 10⁻⁷-1 × 10⁻⁴ M). Administration of ETYA, NDGA, or HQ abrogated the observed vasodilatation to acetylcholine, which was not seen with vehicles alone (P < 0.01). These studies suggest an important role for the endothelium in pulmonary vascular responsiveness to alveolar hypoxia through possible release of a relaxing factor(s) that attenuates the degree of pulmonary arterial constriction.

Introduction

Hypoxic pulmonary hypertension remains a major cause of morbidity and mortality in patients with progressive pulmonary disease (1). Despite the initial description of hypoxic pulmonary arterial constriction in 1946 (2), the mechanism(s) responsible for modulation of vascular smooth muscle contraction have not been clearly elucidated. In 1980, Furchgott and Zawadzki (3) reported that an intact endothelium was important for the relaxation of precontracted vascular rings to acetylcholine, as rings denuded of endothelium failed to vaso-

dilate to acetylcholine. Subsequent studies demonstrated that this endothelium-dependent vasodilation existed for some (acetylcholine, bradykinin, ATP, and AA, etc.) but not all (nitroglycerin, nitroprusside, isoproterenol, and adenosine) vasodilators (4, 5). As the role of the endothelium was investigated further, it was apparent that endothelium-dependent relaxation was due to release of a diffusible factor(s), as the relaxation was transferable in perfusate to vascular strips denuded of endothelium (6). This factor appeared to be a nonprostaglandin substance since vascular responsiveness to endothelium-dependent vasodilators was unchanged by treatment with cyclooxygenase inhibitors (7, 8). However, the actions of these endothelium-dependent relaxing factors (EDRF) were attenuated or blocked by multiple pharmacological agents, including the lipoxygenase antagonists eicosatetrayenoic acid (ETYA) and nordihydroguaiaretic acid (NDGA) (8) and the antioxidant hydroquinone (HQ) (6).

In addition to the evidence for a role of the endothelium in vascular responses to certain vasodilators in these in vitro studies, recent work has demonstrated a possible role for EDRF in the intact pulmonary circulation (9). However, involvement of EDRF in hypoxic pulmonary vasoconstriction has never been characterized. The purpose of this study was to test for a possible role of the endothelium in pulmonary vascular responses to alveolar hypoxia and angiotensin II in the intact pulmonary vascular bed using the isolated perfused lung preparation.

Methods

Isolated perfused lung

The isolated perfused lung preparation originally described by Hauge (10) and modified by McMurtry et al. (11) was used to evaluate the hypoxic pulmonary pressor response. Male Sprague-Dawley rats weighing 300–450 g were anesthetized with 30 mg/kg i.p. pentobarbital sodium (Vet Labs Limited, Inc., Lenexa, KS). After tracheal cannulation, the lungs were ventilated (model 361; Harvard Apparatus Co., S. Natick, MA) with warmed normoxic gas (95% air, 5% CO₂) at a rate of 60 breaths per minute and 2 mmHg positive end-expiratory pressure. Tidal volume was adjusted to maintain a peak inspiratory pressure of 10 mmHg. A median sternotomy was performed and 100 U (0.1 ml) of heparin (Elkins-Sinn, Inc., Cherry Hill, NJ) was injected into the right ventricle. Cannulae were inserted into the pulmonary artery and left ventricle. The heart and lungs were excised carefully and suspended in a humidified chamber at 38°C. The isolated lung preparation was then perfused with whole blood warmed to 38°C at 0.03 ml/g body weight per min, using a peristaltic pump (Critikon, Inc., Tampa, FL). 25–30 ml of whole blood for each experiment was obtained from cardiac puncture of male Sprague-Dawley blood-donor rats weighing > 500 g in heparinized syringes, after deep anesthesia by diethyl ether inhalation (Fisher Scientific Company, Fair Lawn, NJ). This blood was filtered through nylon mesh into a reservoir surrounded by a water...
jacket with circulated water at 38°C. Blood was warmed to 38°C before entering the pulmonary artery by the reservoir and by passing through a perfusion coil bathed by water at 38°C using a circulating water bath (Haake, Inc., Karlsruhe, FRG). Effluent blood from the left ventricle was returned to the reservoir for recirculation. Throughout the experiment, blood pH was maintained between 7.30 and 7.50 by addition of NaHCO₃ (American Hospital Division, Shirley, NJ) to the blood reservoir.

**Measurements**

Pulmonary arterial pressure was measured by a vascular transducer (P23DI-D; Gould Inc., Cleveland, OH) connected to the proximal pulmonary arterial tubing, and a strip-chart record (7754B; Hewlett-Packard Co., Palo Alto, CA). Because perfusion rate was constant, increases in pulmonary arterial pressure reflected increase in pulmonary vascular resistance. Airway pressure was measured using a transducer (MP45-1-871; Validyne Engineering Corp., Northridge, CA) connected to the inspiratory tubing from the ventilator. Effluent blood pH, PO₂, and PCO₂ were measured using appropriate electrodes (model 127; Instrumentation Laboratory, Lexington, MA).

**Protocols**

After institution of perfusion, stable baseline pulmonary pressures were established over at least 30 min. Absolute pulmonary artery pressures before the beginning of each experiment were between 10 and 17.5 mmHg, and increased at a rate < 5 mmHg/h during the protocols (Table I). The lungs were then challenged during normoxic ventilation with 0.25 µg/Asn, Valangiotensin II (Ang II; CIBA Pharmaceuticals, CIBA-Geigy Corp., Summit, NJ), in 0.05 ml of NaCl, which was injected into the pulmonary arterial tubing just proximal to the cannula. This was followed in 5 min by a 6-min period of ventilation with hypoxic gas (Hypox I; 3% O₂, 5% CO₂, 92% N₂) to assess the initial reactivity of the lung vasculature. Any preparation not achieving at least a 5-mmHg increase in pulmonary arterial pressure with this hypoxic challenge was excluded from the study. 5 min after Hypox I, Ang II was again administered. 5 min later, in all protocols, 20 µg/ml sodium meclofenamate (Warner-Lambert Co., Ann Arbor, MI) in 0.1 ml of 0.9% NaCl was added to the effluent blood returning to the reservoir to eliminate the possibility that effects of other inhibitors subsequently administered were due to cyclooxygenase inhibition or to shunting of the arachidonate cascade to the cyclooxygenase pathway, 5 min after the administration of meclofenamate, the lungs were challenged with three periods of alternating injection of 0.25 µg Ang II via the pulmonary artery (Ang II-2 to Ang II-4) and 6 min of hypoxic ventilation (Hypox II to Hypox IV), each separated by 5-min intervals for recovery. Effluent blood pH and gas tensions were pH 7.38±0.004, PO₂ 120±2 mmHg, and PCO₂ 31±1 mmHg during normoxia, and pH 7.41±0.002, PO₂ 29±0.4 mmHg, and PCO₂ 28±0.4 mmHg during the fourth minute of hypoxia (mean±SE, n = 48). Vascular reactivity to hypoxia in the isolated perfused rat lung has been previously observed to increase progressively from the first through the fourth hypoxic challenge and then plateau (11, 12). To minimize the effect of this change in reactivity, antagonists and their vehicles were administered after Hypox IV. Therefore, 5 min after Hypox IV, vehicles or chemically dissimilar putative antagonists of EDRAF were added to the reservoir blood. 5 min thereafter, four periods of alternating 0.25 µg Ang II (Ang II-5 to Ang II-8) via the pulmonary artery, and hypoxic ventilation for 6-min periods (Hypox V to Hypox VIII) were evaluated for changes in pulmonary vascular reactivity. The following protocols were performed by administration of vehicles or antagonists between Hypox IV and Hypox V:

(a) Normal saline alone (n = 8). To evaluate for changes in reactivity of our preparation and to control for the effects of vehicles, a separate set of experiments was performed in which 0.05 ml 0.9% NaCl was injected into the reservoir blood between Hypox IV and Hypox V.

(b) ETYA or NDGA (n = 8). Both 1 × 10⁻⁴ M ETYA and 1 × 10⁻⁴ M NDGA have been shown to antagonize endothelium-dependent relaxation responses to acetylcholine in precontacted rabbit thoracic aortic segments (8). Therefore, 5, 8, 11, 14-ETYA (Ro-31-4282; Hoffmann-La Roche, Inc., Nutley, NJ) in 0.05 ml DMSO (Fisher Scientific Co.) was added to the reservoir blood for an ETYA final concentration of 1 × 10⁻⁴ M between Hypox IV and Hypox V and remained for the duration of the experimental protocol. In a separate protocol, NDGA (Sigma Chemical Co., St. Louis, MO) in 0.05 ml DMSO was added to the reservoir blood for a reservoir NDGA concentration of 1 × 10⁻⁴ M, between Hypox IV and Hypox V (n = 8) and was present through the rest of the protocol. An additional separate group of studies was performed in which the vehicle DMSO (0.05 ml) was added to the reservoir blood between Hypox IV and Hypox V to determine the effects of the vehicle alone.

(c) Hydroquinone (HQ) (n = 8). Previous investigators (5) have observed that the antioxidant 1,4-benzenediol (1 × 10⁻⁴ M HQ) abolished relaxation of vascular rings to acetylcholine. Therefore, HQ (Sigma Chemical Co.) in 0.05 ml 0.9% ethyl alcohol (ETOH; U.S. Industrial Chemicals Co., Tuscola, IL), was added to the reservoir blood for an HQ concentration of 1 × 10⁻⁴ M between Hypox IV and Hypox V and was present through the rest of the protocol. A separate group of studies was performed in which the vehicle ETOH (0.05 ml) was added to the reservoir blood between Hypox IV and Hypox V to observe the effects of vehicle alone.

**Efficacy of inhibitors to block endothelium-dependent vasodilators**

To assess whether these EDRAF inhibitors blocked a known endothelium-dependent vasodilatory response in the isolated perfused rat lung, studies were performed in a separate group of isolated blood-perfused lungs prepared as described above. Initial responsiveness of the pulmonary vascular bed to Ang II and hypoxia was established, after which vascular resistance was elevated by the addition of nor epinephrine (NE; Sigma Chemical Co.) in 0.05 ml 0.9% NaCl to result in a reservoir blood concentration of 1 × 10⁻⁴ M. 2 min after the NE following peak pulmonary vasoconstriction, edrophonium chloride (Sigma Chemical Co.) was administered in 0.05 ml 0.9% NaCl to attain a reservoir blood concentration of 1 × 10⁻⁴ M. Edrophonium was administered to block the acetylcholine esterase activity of red blood cells and the vasculature, which could obscure vascular responses to acetylcholine (13). 2 min later, the endothelium-dependent vasodilator acetylcholine chloride (Sigma Chemical Co.) was administered in 0.05 ml 0.9% NaCl in increasing doses at 1-min intervals into the pulmonary artery to achieve total reservoir blood acetylcholine concentrations of 1 × 10⁻⁷, 1 × 10⁻⁶, 1 × 10⁻⁵, and 1 × 10⁻⁴ M. Acetylcholine solutions were prepared by thawing and diluting previously prepared stock solutions of acetylcholine in 0.9% normal saline. After 10 min for recovery, either ETYA (1 × 10⁻⁴ M, n = 6), NDGA (1 × 10⁻⁴ M, n = 6), or HQ (1 × 10⁻⁴ M, n = 6) was added to the reservoir blood, followed in 5 min by identical administration of 1 × 10⁻⁴ M edrophonium into the reservoir blood. Acetylcholine was injected again in identical doses into the pulmonary artery at 1-min intervals. A separate group of experiments was performed in lungs treated as above except that either vehicle DMSO (0.05 ml, n = 6) or vehicle ETOH (0.05 ml, n = 6) was added to the reservoir blood rather than inhibitors to determine the effects of these vehicles alone.

**Statistical analysis**

The rise in pulmonary artery pressure (ΔPA) with Ang II and hypoxic ventilation was calculated for each of eight periods in each protocol. Changes in the ΔPA within each protocol were identified by one-way analysis of variance and Student-Newman-Keuls' multiple comparisons test (14). T statistics calculated from the least-squares means and pooled variance adjusted for subject-specific period IV pulmonary arterial pressure changes were performed to evaluate changes in ΔPA between vehicles and inhibitors. Statistical significance was identified when P < 0.05. In the text, tables, and figures, data are expressed as mean±SE.

**Results**

**Effects of normal saline (Table I, Fig. 1).** Baseline pulmonary artery pressure was stable and increased at a rate of < 5
mmHg/h during the various treatment and vehicle protocols (Table I). The rise in pulmonary arterial pressure with hypoxia was stable with repeated hypoxic challenges (Fig. 1). Addition of normal saline to the reservoir blood between the fourth and fifth hypoxic challenges failed to alter the rise in pulmonary artery pressure induced by hypoxia. The ΔPA in response to Ang II was increased after meclofenamate administration (period II compared with period I, P < 0.01) in this and in all subsequent protocols (Fig. 1).

Effect of ETYA or NDGA (Figs. 2–4). Baseline pulmonary artery pressure before all hypoxic challenges were comparable among the ETYA, NDGA, and DMSO protocols and rose at a rate of < 4 mmHg/h in all groups (Table I). There was no significant difference in the hypoxic pressor response between any of the protocols during the first four hypoxic challenges. Administration of the vehicle DMSO to the reservoir blood between the fourth and fifth hypoxic challenge resulted in no significant change in the ΔPA response to hypoxic ventilation (Figs. 2 and 3). In striking contrast, the addition of either ETYA (Fig. 2) or NDGA (Fig. 3) to the reservoir blood between Hypox IV and Hypox V resulted in a marked augmentation (P < 0.05) of the hypoxic pressor response that persisted through the eighth period, which was significantly different (P < 0.05) from the response obtained with DMSO alone. In contrast to the hypoxic pressor response, the rise in pulmonary arterial pressure to 0.25 μg Ang II was augmented by administration of DMSO (Fig. 4). Comparable increases in the pressor responses to Ang II were observed after administration of either ETYA or NDGA (Fig. 4).

Table I. Change in Baseline Pulmonary Arterial Pressure

<table>
<thead>
<tr>
<th>Protocol</th>
<th>Baseline pulmonary artery pressure before Hypox I (mmHg)</th>
<th>Rate of rise in pulmonary artery pressure during protocol (mmHg/h)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Normal saline</td>
<td>15±1</td>
<td>2±1</td>
</tr>
<tr>
<td>ETYA</td>
<td>18±1</td>
<td>2±1</td>
</tr>
<tr>
<td>NDGA</td>
<td>14±1</td>
<td>4±1</td>
</tr>
<tr>
<td>DMSO</td>
<td>16±1</td>
<td>3±1</td>
</tr>
<tr>
<td>HQ</td>
<td>16±1</td>
<td>5±1</td>
</tr>
<tr>
<td>ETOH</td>
<td>17±1</td>
<td>3±1</td>
</tr>
</tbody>
</table>

![Figure 1](image1.png)

Figure 1. Administration of normal saline between Hypox IV and Hypox V was not associated with any change in the hypoxic pressor response in the subsequent periods. Pulmonary arterial pressure responses to Ang II injection remained stable during the protocol. n = 8, *, hypoxic ventilation; #, Ang II injection.

![Figure 2](image2.png)

Figure 2. The administration of 1 × 10⁻⁴ M ETYA between Hypox IV and Hypox V resulted in a marked accentuation of the hypoxic pressor response in subsequent periods, as compared with the vehicle DMSO. n = 8, #, ETYA, o, DMSO. *Significantly different from periods III and IV, P < 0.05. **Significant difference between the change in response from period IV to the subsequent period after ETYA compared with the change between comparable periods with DMSO, P < 0.05.

![Figure 3](image3.png)

Figure 3. The administration of 1 × 10⁻⁴ M NDGA between Hypox IV and Hypox V markedly potentiated the hypoxic pressor response in subsequent periods as compared with the vehicle DMSO. n = 8, #, NDGA, o, DMSO. *Significantly different from periods III and IV, P < 0.05. **Significant difference between the change in response from period IV to the subsequent period with NDGA compared with the change between comparable periods with DMSO, P < 0.05.
Efficacy of inhibitors to block endothelium-dependent vasodilators (Figs. 7 and 8). Pulmonary arterial administration of acetylcholine (Figs. 7 and 8) resulted in a dose-dependent relaxation of the NE-precontracted pulmonary vasculature after pretreatment with edrophonium in all studies before the addition of ETYA, NDGA, or HQ or the vehicles DMSO or ETOH to the reservoir blood (P < 0.05). The addition of the vehicles DMSO or ETOH resulted in no significant change in this acetylcholine-induced pulmonary arterial vasodilation (Figs. 7A and 8A). Administration of ETYA, NDGA, or HQ to the reservoir blood completely abolished the relaxation response to acetylcholine and instead a mild increase (P < 0.05) in pulmonary arterial pressure was observed (Figs. 7B and C, and Fig. 8B). The changes in pulmonary arterial pressure responses to acetylcholine after ETYA, NDGA, or HQ administration were significantly different from those seen after vehicle administration.

Discussion

Although the pulmonary arterial constrictor response to alveolar hypoxia has been investigated extensively, its precise mechanism and factors that modulate the vasoconstriction have not been clearly explained. This study demonstrated that the chemically dissimilar EDRF inhibitors ETYA, NDGA, and HQ all augmented the hypoxia-induced ΔP in the denervated but otherwise intact pulmonary circulation of the isolated perfused rat lung. In addition, pulmonary vasodilation was observed with administration of the endothelium-dependent vasodilator acetylcholine, and this vasodilation was abolished by pretreatment with the EDRF inhibitors ETYA, NDGA, and HQ.

These studies were conducted using an isolated, denervated lung preparation and suggest that the endothelium is an important modulator of the hypoxic pressor response. Pulmonary arterial constriction has been shown to occur in response to alveolar hypoxia in vivo with ventilation of one lung with hypoxic gas (15). Furthermore, isolated, denervated, saline-perfused rat lungs have exhibited continued pressor responses to hypoxic ventilation (11). These observations imply that the sensors and effectors for hypoxic pulmonary vasoconstriction function locally for control of blood flow, and the response is independent of substantial influence from the autonomic nervous system or systemic humoral substances (16). Although some investigators have suggested that pulmonary arterial constriction is due to direct effects of hypoxia on vascular smooth muscle cellular membrane ion transport mechanisms (17) and excitation-contraction coupling (11), recent studies have emphasized the importance of the endothelium in mediating vascular responsiveness to hypoxia. DeMey and Vanhoutte (18) observed that augmentation by anoxia of canine femoral artery strip contraction to NE was enhanced by the presence of an intact endothelium; they went on to document the same finding in pulmonary artery strips (19). Peach et al. (5) found that anoxia produced an endothelium-dependent vasoconstriction in rabbit and rat aorta. Holden and McCall (20) showed that an intact endothelium was necessary for hypoxia-induced contractions of in vitro main pulmonary artery strips from pigs. The question that is raised by these investigations is whether hypoxia causes the release of a vasoconstrictor substance (21, 22) or rather interrupts the production, release, and/or action of a vasodilator substance from the endothelium that exerts modulating effects on vascular smooth muscle responses to hypoxia.

Since Furchgott and Zawadzki (3) first demonstrated that rat aortic strips would relax in response to acetylcholine only
in the presence of an intact endothelium, numerous investigators have identified endothelium-dependent vasodilatory capacity with a large number of substances and in a wide variety of vascular tissue sources (23). The hypothesis was put forth that acetylcholine resulted in the release of a factor(s) that, on diffusing to the subadjacent smooth muscle cells, activated a

Figure 7. (A) In the presence of NE-induced elevated resistance, the pulmonary arterial vasodilatory response to acetylcholine injection at increasing doses was unchanged by administration of vehicle (DMSO). o, before DMSO administration; e, after DMSO administration. (B) Administration of the in vitro EDRF inhibitor EYA (1 x 10^{-4} M) resulted in a loss of the pulmonary arterial vasodilatory response to acetylcholine injection. o, before EYA administration; e, after EYA administration. (C) Administration of the in vitro EDRF inhibitor NDGA (1 x 10^{-4} M) resulted in a loss of the pulmonary arterial vasodilatory response to acetylcholine injection. o, before NDGA administration; e, after NDGA administration. *Significantly different from the change in pulmonary artery pressure seen with the same dose of acetylcholine after EYA or NDGA administration as compared with after DMSO administration alone, P < 0.01.

Figure 8. (A) In the presence of NE-induced elevated resistance, the pulmonary arterial vasodilatory response to acetylcholine injection at increasing doses was unchanged by administration of vehicle (ETOH). o, before ETOH administration; e, after ETOH administration. (B) Administration of the in vitro EDRF inhibitor HQ (1 x 10^{-4} M) resulted in a loss of the pulmonary arterial vasodilatory response to acetylcholine injection. o, before HQ administration; e, after HQ administration. *Significantly different from the change in pulmonary artery pressure seen with 10^{-7} M acetylcholine injection, P < 0.05. *Significant difference between the change in pulmonary artery pressure seen with the same dose of acetylcholine after HQ administration as compared with after ETOH administration alone, P < 0.01.
mechanism for relaxation (3). Further studies showed that endo-
theelium-dependent relaxation could be restored to strips de-
nuded of endothelium by apposition with, or superfusion from
intact endothelium (3, 6, 21). These studies clearly docu-
mented that a diffusible vasodilator was released from the in-
tact endothelium in response to a stimulator. Attempts to
identify the nature of this transferable EDRF led investiga-
tors to describe a number of substances that blocked endothelium-
dependent relaxation in arterial strips without affecting the
activity of endothelium-independent vasodilators such as so-
dium nitroprusside. These in vitro EDRF inhibitors included
the lipoxygenase inhibitor EYTA (3), the lipoxygenase inhibi-
tor and antioxidant NDGA (24), and the antioxidant HQ (6).
Although the nature of EDRF has never been clearly ex-
plained, the activities of these EDRF inhibitors have led in-
vitro experiments to propose a number of possible sources for EDRF,
including oxidative products of the lipoxygenase or epoxygen-
ase pathways of arachidonate metabolism (25–27). Further
studies showed that pulmonary artery strips had the capacity
to respond to endothelium-dependent vasodilators (7, 28).

In view of these previous investigations, the results pre-
sented here demonstrate endothelium-dependent vasodilation
in the pulmonary vascular bed, and are consistent with an
important role of the endothelium in the modulation of the
hypoxic pressor response of the intact pulmonary vascular bed
through the release of EDRF. These observations confirm pre-
vious studies that document that the endothelium-dependent
vasodilators acetylcholine (29), A23187 (30), and histamine
(31) have been shown to dilate the rat pulmonary circulation.
Cherry and Gillis (9) observed recently that dose-dependent
vasodilatory responses to acetylcholine in precontracted in situ
indomethacin-treated rabbit lungs were blocked by admin-
istration of the EDRF inhibitors quinacrine and hemoglobin.
Moreover, the putative in vitro EDRF inhibitor BW 755C (26)
enhanced the pulmonary hypoxic pressor response in intact
anesthetized dogs with acute left lower lobe atelectasis (32).
Together, the present observations and these previous studies
support a role for EDRF in the modulation of pulmonary
vascular tone.

The question could be raised whether the EDRF antago-
nists enhanced hypoxic vasoconstriction through inhibition of
basal release of EDRF, or blockade of enhanced EDRF release
during hypoxia. As EDRF inhibition during normoxic venti-
lation did not significantly affect baseline pulmonary artery
pressures or the rate of rise in baseline pressures as compared
with vehicle controls (Table I), it is unlikely that this augmenta-
tion of hypoxic vasoconstriction was due to a decrease in basal
EDRF activity, although the possibility of some effect by
the inhibitors on basal EDRF release has not been fully ex-
cluded. The accentuation of the hypoxic pressor response by
EDRF inhibition implies that EDRF activity is increased dur-
ing hypoxia.

An increase in EDRF activity with hypoxia could be chal-
enged by previous suggestions that anoxia diminished endo-
theelium dependent relaxation responses in vitro (18, 19). How-
ever, Chand and Altura (7) showed that hypoxia had no effect
on acetylcholine-induced endothelium-dependent vasodilata-
tion. Recent studies have demonstrated that isolated perfused
rat lungs preconstricted by alveolar hypoxia retain the ability
to vasodilate in response to acetylcholine (29), A23187 (30),
and arachidonate (33). Hypoxic vasoconstriction has been
shown to stimulate the release of PG12 (33) and 5-hydroxy-
eicosatetraenoic acid (34), a product of the 5-lipoxygenase
pathway of arachidonate metabolism, into the effluent from
isolated saline-perfused rat lungs demonstrating that eicosan-
oid production is stimulated by hypoxic ventilation, including
metabolites of arachidonate that may include EDRF. To-
gether, these studies suggest that although anoxia is an inhibi-
tor of EDRF activity, lesser degrees of hypoxia do not inhibit
and may stimulate EDRF production and release.

Whereas the specificity of ETYA, NDGA, and HQ as inhibi-
bitors of EDRF when used in an intact blood-perfused circu-
lation has never been documented, there is supportive evi-
dence that these agents inhibited endothelium-dependent re-
lex in the studies presented here: (a) although the possibility exists with each of these inhibitors of effects inde-
dependent of EDRF, the consistent enhancement of hypoxic vaso-
constriction by three chemically dissimilar antagonists
strongly supports a common mechanism, i.e., inhibition of
EDRF; (b) we have documented that ETYA, NDGA, and HQ
each blocked acetylcholine-induced endothelium-dependent
vasodilation in the denervated whole blood-perfused rat lung;
and (c) ETYA, NDGA, and HQ have previously been ob-
erved to antagonize endothelium-dependent relaxation in nu-
erous studies (3, 6, 24). In this study, Ang II vasoconstriction was potentiated by
cyclooxygenase inhibition and by the vehicles DMSO and
ETOH, but was not further enhanced by the putative EDRF
inhibitors ETYA, NDGA, and HQ. The accentuation of Ang
II vasoconstriction by cyclooxygenase inhibition in the iso-
lated perfused rat lung has been previously described by Voel-
kel et al. (33). A previous study by Yilmaz et al. (35) observed
heightening of Ang II constriction of rabbit aortic strips by HQ
denudation of the endothelium, but not by aspirin admin-
istration. However, these observations conflict with studies
from one of our laboratories, which found no effect on Ang II
responsiveness of rabbit thoracic aorta by denudation of the
endothelium or by a number of EDRF inhibitors (8). Despite
this conflict between our previous studies and the observations
by Yilmaz et al., several additional explanations may be con-
sidered for the absence of augmentation of Ang II responsive-
ness by EDRF antagonists in our cyclooxygenase inhibited
preparation: (a) there may be differences in reactivity between
systemic and pulmonary vessels and between whole blood
perfused vascular beds and larger vessels studied in ring prepa-
rations; and (b) it is unclear why the vehicles alone heightened
Ang II constriction in this study, but may be related to endo-
theelium-independent mechanisms directly involving the vas-
cular smooth muscle (36). Nevertheless, this effect of the vehi-
cles may have masked further potentiation of Ang II vasocon-
striction by the putative EDRF antagonists. Unfortunately, we
have no direct information from this study on these possibili-
ites.

It is unlikely that the inhibitors enhanced hypoxic pulmo-
nary vasoconstriction through diminished prostacyclin pro-
duction from cyclooxygenase inhibition, although one of the
antagonists, ETYA, is an inhibitor of cyclooxygenase (37). In
the experiments presented here, 20 μg/ml meclofenamate was
added to the reservoir blood to remove any possible effects by
the products of the cyclooxygenase pathway. The early admin-
istration of meclofenamate in all protocols resulted in no sig-
nificant change in the hypoxic pressor response, which is dif-
fent from previous observations by McMurtry et al. McMurtry et al. (11) previously has shown an increase in hy-
hypoxic vasoconstriction after meclofenamate but used a lower dose (2 μg/ml) and administered it later after hypoxic responses had reached a plateau or started to decline. Morganroth et al. (38) used the meclofenamate concentration of 20 μg/ml to inhibit the cyclooxygenase pathway in the isolated saline-perfused rat lung. Although Voelkel et al. (33) found that a higher meclofenamate dose of 50 μg/ml was required to completely reverse the vasodilatory effects of arachidonate infusion in a blood-perfused lung, administration of less than one tenth of that dose already has been shown to markedly elevate the baseline pulmonary artery pressure in the isolated perfused rat lung (11). As it is highly unlikely that the cyclooxygenase pathway plays an important role in EDRF activity, and because an elevation of the pulmonary artery pressure baseline might significantly affect the results of these experiments, we used a concentration of 20 μg/ml reservoir blood. This dose resulted in an augmentation of the pressor responses to Ang II administration comparable to that which had been seen with the higher dose of meclofenamate in the blood-perfused rat lung (33).

Previous investigators have suggested that hypoxic vasoconstriction is mediated by products of the lipoxygenase pathway of arachidonate metabolism (34, 38). The results presented here argue against a significant role for lipoxygenase metabolites in the vasoconstrictor response to hypoxia, as ETYA and NDGA (both lipoxygenase inhibitors) resulted in an accentuation rather than a diminishishment of the hypoxic pressor response.

In summary, the results presented in this study demonstrate that the in vitro antagonists of EDRF significantly augment the hypoxic pulmonary pressor response in a denervated but otherwise intact pulmonary vascular bed. This suggests that during hypoxia, the endothelium releases relaxing factor(s) that limit or attenuate the degree of vasoconstriction.

Acknowledgments

We would like to thank Hoffmann-La Roche Inc. for providing ETYA. The sodium meclofenamate used in this study was kindly provided by Warner-Lambert Co. We wish to thank Ms. Elizabeth Crawford for typing the manuscript.

This work was supported by the Virginia Affiliate, American Heart Association, and by National Institutes of Health research awards HL-28118 and F32 HL-07134.

References


